News
IMMX
9.94
-1.58%
-0.16
Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis
PUBT · 1d ago
Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis
PUBT · 3d ago
Weekly Report: what happened at IMMX last week (0504-0508)?
Weekly Report · 5d ago
Immix Biopharma Q1 net loss widens to USD 10.09 million
PUBT · 05/07 22:20
Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis
PUBT · 05/04 18:15
Weekly Report: what happened at IMMX last week (0427-0501)?
Weekly Report · 05/04 10:34
Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis
PUBT · 05/03 15:36
Weekly Report: what happened at IMMX last week (0420-0424)?
Weekly Report · 04/27 10:38
Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX) and Vertex Pharmaceuticals (VRTX)
TipRanks · 04/23 10:31
Weekly Report: what happened at IMMX last week (0413-0417)?
Weekly Report · 04/20 10:33
Citizens biotechnology analyst holds analyst/industry conference call
TipRanks · 04/14 18:20
Weekly Report: what happened at IMMX last week (0406-0410)?
Weekly Report · 04/13 10:38
Immix Biopharma to participate in Jefferies Global Healthcare Conference, hosts investor meetings
Reuters · 04/09 12:45
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Barchart · 04/09 07:45
Immix Biopharma announces annual shareholder meeting
Reuters · 04/06 20:38
Weekly Report: what happened at IMMX last week (0330-0403)?
Weekly Report · 04/06 10:38
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201
TipRanks · 03/30 22:49
Immix Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 03/30 17:43
HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $15 Price Target
Benzinga · 03/30 17:33
Immix Biopharma Price Target Raised to $15.00/Share From $14.00 by Mizuho
Dow Jones · 03/30 14:17
More
Webull provides a variety of real-time IMMX stock news. You can receive the latest news about Immix Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.